You're conflating revenue with reporting.
If there is no business to report, reporting won't do anything, or will cause the stock to drop.
What we are seeing, through newspaper reports, summaries from government, papers, and DD such as Duke's and trevor's earlier today, is that Innova is aggressively pursuing big contracts, bundled with QDX HEALTHID. It's the revenue from those contracts which will fuel the price rise.
Innova best out 40 other companies in the UK for their contracts. Those in charge are happy with the results but there are detractors. All I can say to them is if Innova is bad all the others must have stunk like skunks to lose out.
You are right that catching up the SEC Reports after revenue is reported will attract new OTC investors, but right now we're watching the Chef mix the batter and bake the cookies we will enjoy when they are done. It sounds like your attitude is that baking the cookies takes too long and you just want to eat cookie dough. That's OK. If you want to start a cookie dough company that sell unfinished food, go ahead. Innova is selling finished product - ecosystems, really - with full features to deep pocket, high volume clients.
My feeling is that because of the bundling beforehand, rather than marketing QDXH as an add-on, then QDXH gets it's part of every sale. Do you see that?
QDXH is part of the QMC ecosystem. Besides the all important health status reporting, there is possibly QMC-made gold NP used in the test, QD anticounterfeiting on the test and outer package, and perhaps Covid AI to aid tracking and tracing.
Let's talk revenue. Last question-
$900M in sales so far in the UK
Innova manufactures the tests and takes the risk. QDXH supplies features listed above.
How much revenue do you think is QMC'S?
50% $450M?
40%
30%
20%
10% $90M?
LESS?
What P/E Multiplier would be used?
What's the new stock price then?
If there is no business to report, reporting won't do anything, or will cause the stock to drop.
What we are seeing, through newspaper reports, summaries from government, papers, and DD such as Duke's and trevor's earlier today, is that Innova is aggressively pursuing big contracts, bundled with QDX HEALTHID. It's the revenue from those contracts which will fuel the price rise.
Innova best out 40 other companies in the UK for their contracts. Those in charge are happy with the results but there are detractors. All I can say to them is if Innova is bad all the others must have stunk like skunks to lose out.
You are right that catching up the SEC Reports after revenue is reported will attract new OTC investors, but right now we're watching the Chef mix the batter and bake the cookies we will enjoy when they are done. It sounds like your attitude is that baking the cookies takes too long and you just want to eat cookie dough. That's OK. If you want to start a cookie dough company that sell unfinished food, go ahead. Innova is selling finished product - ecosystems, really - with full features to deep pocket, high volume clients.
My feeling is that because of the bundling beforehand, rather than marketing QDXH as an add-on, then QDXH gets it's part of every sale. Do you see that?
QDXH is part of the QMC ecosystem. Besides the all important health status reporting, there is possibly QMC-made gold NP used in the test, QD anticounterfeiting on the test and outer package, and perhaps Covid AI to aid tracking and tracing.
Let's talk revenue. Last question-
$900M in sales so far in the UK
Innova manufactures the tests and takes the risk. QDXH supplies features listed above.
How much revenue do you think is QMC'S?
50% $450M?
40%
30%
20%
10% $90M?
LESS?
What P/E Multiplier would be used?
What's the new stock price then?
